Chase Therapeutics Corporation

Quick facts

Phase 2 pipeline

• CTC-501 · Oncology
  CTC-501 is a CD47-SIRPα inhibitor, which works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chase Therapeutics Corporation portfolio CI brief
• Chase Therapeutics Corporation pipeline updates RSS

Related

• Sector hub: All tracked pharma companies